All current and expired Paxlovid doses with an EUA label must be returned to the manufacturer or disposed of properly, according to the agency.
The revision comes nearly 10 months after the FDA approved Pfizer’s new drug application for Paxlovid to treat COVID-19 in adults at high -risk of severe complications, including hospitalization or death. Pharmacies and healthcare providers may now only dispense the drug with this NDA labeling.
Paxlovid is still authorized for emergency use in pediatric patients 12 and up.
Learn more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
